Justification of the possibility of using liquid artificial lung ventilation for the treatment of acute respiratory distress syndrome of toxic genesis
Authors: Isabekov Nikolay R. , Tonshin Anton A. , Bonitenko Evgenij Yu. 
Published: September 2024

Introduction. Pulmonotoxicants are chemicals that cause bronchospasm and damage to the alveolar capillary membrane. Lesions of the respiratory system with pulmonotoxicants in industrial accidents are especially relevant at the present time. Existing methods of treatment for the defeat of pulmonotoxicants and the development of acute respiratory distress syndrome (ARDS) are becoming ineffective, therefore, one of the tasks of modern medicine is to develop new methods of treating ARDS. One of these methods may be the creation of a "therapeutic window" by using perfluorocarbon (PFC) liquids. This article will present an experimental assessment of the use of liquid artificial lung ventilation (LALV) PFC liquids on the ARDS lung model.
The study aims to explore the possibility of using liquid artificial lung ventilation to create a therapeutic window in the treatment of acute respiratory distress syndrome of a chemical nature.
Materials and methods. The authors conducted a study on male Wistar rats aged 4 months, weighing 180–190 g. Toxic pulmonary edema was caused by endotracheal administration of 0.1 m HCl solution. The anesthetized patients were intubated using a cannula, after which the researchers intratracheally injected 0.1 M HCl solution at a dose of 2 ml/kg, a decrease in saturation below 80 was expected. Then the experts randomized the animals by weight into groups of 6 individuals each. They connected the animals of the control group to a ventilator. The animals of the experimental group were treated with PFC liquids for an hour, then transferred to a ventilator. Perfluorodecalin was used as a PFC liquid. The scientists recorded heart rate, blood oxygen saturation, rectal temperature, life expectancy and overall survival by group.
Results. In the control group, after instillation of 0.1 M HCl solution and connection to a ventilator during the first 25–30 minutes, there was a gradual decrease in SpO2 to 74.0±5.6% (background — 95.0±3.5%) and an increase in heart rate to 182.0±8.6 beats/min., (background — 278.0±14.8 beats/min.) after which there was decompensation of the animal condition. In animals of the experimental group, after connecting to the LALV device, a sharp decrease in heart rate was recorded during the first 5 minutes to 61.0±8.5 beats/min. In turn, saturation did not change significantly throughout the LALV and was in the range from 95 to 100%. As a result of the experiments, it was noted that the average survival time in the experimental group was 256.0±34.5 minutes, which was significantly (p<0.001) more than 5 times higher than this indicator in the control animals — 45.3±4.3 minutes.
There were no significant changes in the study of rectal temperature in the animals of the control group. In turn, the animals of the experimental group showed a sharp decrease in rectal temperature during the first 30 minutes from the beginning of LALV, on average by 5.8±1.60°С.
As a result of the pathoanatomic autopsy, differences in lung mass coefficients were revealed in different groups. Thus, in the control group and the experimental groups, it was 1.67±0.06 and 2.4±0.045%, respectively.
Conclusion. On the model of ARDS caused by endotracheal administration of 0.1M hydrochloric acid solution, it was shown that living with the use of PFC of low temperature liquids, unlike conventional mechanical ventilation, allows for a long time to maintain a stable condition of animals; evacuate a significant amount of edematous fluid from the lungs and thereby increase the duration of their survival. The data presented above indicate that the use of hypothermic LALV can be used to create a "therapeutic window" for ARDS, including its most severe form — the alveolar stage of toxic pulmonary edema.
Ethics. Studies involving laboratory animals were conducted in compliance with the following regulations: the Helsinki Declaration of 2000 "On humane treatment of animals", Order No. 755 of the Ministry of Health of the USSR dated 08/12/1977 "Rules for carrying out work using experimental animals", Order No. 199n of the Ministry of Health of the Russian Federation dated 04/01/2016 "On approval of the rules of laboratory practice". The protocol of the study was approved by the Ethics Committee of the Izmerov Research Institute of Occupational Health. Protocol No. 4 dated May 25, 2022.